Stoke Therapeutics Inc is a pioneering biopharmaceutical firm focused on developing innovative treatments for severe genetic diseases. With a unique approach using antisense oligonucleotides, the company aims to restore protein levels in patients. Its leading projects include STK-002 for autosomal dominant optic atrophy and STK-001 for Dravet syndrome, among others targeting central nervous system and eye diseases. Based in Bedford, Massachusetts, Stoke Therapeutics has formed a significant partnership with Acadia Pharmaceuticals to advance RNA-based medicines for rare neurodevelopmental conditions.
Thursday's top analyst upgrades and downgrades included Albertsons Companies, Alphabet, Apple, Coinbase Global, Danaher, Enphase Energy, GE HealthCare Technologies, General Electric, McDonald's, Microsoft, PulteGroup and Tesla.
Monday's top analyst upgrades and downgrades included AT&T, ADM, Chevron, FedEx, Intel, Meta, Qualcomm and more.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Monday, including in Barrick, Nordstrom, Lyft and Twitter.
